Lucentis is a vascular endothelial growth factor (VEGF) inhibitor approved by the U.S. Food and Drug Administration (FDA) for the treatment of neovascular (wet) age-related macular degeneration (AMD). Lucentis is the only FDA-approved …
Adverse events were consistent with those observed in clinical trials of MACUGEN in patients with neovascular agerelated macular degeneration (wet AMD) and similar to clinical experience with MACUGEN. About Diabetic Macular Edema (DME) …
Macular degeneration is a disease in which the heart loses sight of. If you advanced disease, only peripheral vision. People who are older, a higher risk of developing the disease. It is aimed at research important to protect the …
